Drug ApprovalLicense out/inImmunotherapyCell TherapyPhase 3
Ipsen and Marengo Therapeutics, have inked a partnership to advance two preclinical candidates from Marengo’s STAR platform into clinical development.
The collaboration aims to leverage Marengo’s innovative T cell activation technology and Ipsen’s extensive global oncology infrastructure to develop new oncology treatments.
Under the terms of the agreement, Ipsen will make an upfront payment of $45 million to Marengo, with potential milestone payments that could total up to $1.592 billion, plus tiered sales royalties. Marengo will lead preclinical development efforts and cover related costs until the submission of an Investigational New Drug application to the U.S. FDA. Ipsen will assume responsibilities for clinical development and commercialization following the IND submission.
Ipsen focuses on developing drugs in oncology, rare diseases, and neuroscience. Marengo Therapeutics, an ATP company, specializes in developing therapeutics that activate specific T cell responses to combat cancer. Marengo’s STAR platform creates selective T cell activators aimed at generating functional, cancer-killing T cells for solid tumors.
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.